期刊文献+

小檗碱联合绿原酸抗骨质疏松的作用机制 被引量:1

Study on the mechanism of the anti-osteoporosis effect of berberine combined with chlorogenic acid
下载PDF
导出
摘要 目的 研究小檗碱联合绿原酸对MC3T3-E1细胞分化作用及对绝经后骨质疏松小鼠的干预作用,并探讨其可能的机制。方法 观察小檗碱、绿原酸及两药联用对MC3T3-E1细胞增殖和分化能力的影响,并检测细胞中Wnt3a、β-catenin及成骨分化相关基因mRNA的表达水平。在体构建绝经后骨质疏松症小鼠模型,随机分为模型组、小檗碱组、绿原酸组及两药联用组,同时设置假手术组为对照,尾静脉给药8周后处死小鼠,检测其血清BALP、BGP含量,Micro-CT扫描观察小鼠股骨微结构变化,免疫组织化学法检测小鼠股骨Wnt3a和β-catenin蛋白表达,HE染色观察小鼠重要器官的组织病理结构变化。结果 与正常组相比,小檗碱组、绿原酸组及两药联用组对MC3T3-E1细胞增殖率无明显影响,但均可促进MC3T3-E1细胞成骨分化能力和矿化水平,以两药联用组最明显;并且两药联用组能显著升高Wnt3a、β-catenin、ALP、Runx2、OPN和OCN mRNA的表达(P<0.01)。体内实验表明,与模型组相比,两药联用组小鼠血清BALP、BGP含量明显降低,股骨微观结构得到明显改善,股骨Wnt3a和β-catenin蛋白表达明显升高(P<0.05),并对小鼠重要器官组织切片无明显损伤性改变,表现出良好的生物安全性。结论 小檗碱联合绿原酸可促进MC3T3-E1细胞成骨分化和改善去势小鼠部分骨质疏松表型特征,其机制可能与激活Wnt3a/β-catenin信号通路有关。 Objective To study the effect of berberine(Ber)combined with chlorogenic acid(CA)on the differentiation of MC3T3-E1 cells and the intervention effect on postmenopausal osteoporosis mice,and to explore the possible mechanism.Methods The effects of Ber,CA,and Ber+CA on the proliferation and differentiation capacity of MC3T3-E1 cells were observed.The mRNA expression levels of Wnt3a,β-catenin and osteogenic differentiation-related genes in MC3T3-E1 cells were detected.Forty female mice were randomly divided into sham operation group,osteoporosis model group,Ber group,CA group,and Ber+CA group.They were sacrificed 8 weeks after caudal intravenous administration.Serum BALP and BGP contents of the mice were detected.The microstructure changes of the femur were observed with micro-CT scanning.The protein expressions of Wnt3a andβ-catenin in the femur was detected with immunohistochemistry.The histopathological structure changes of the important organs were observed by HE staining.Results The proliferation rate of MC3T3-E1 cells were not influenced in Ber group,CA group,and Ber+CA group,bu the osteogenic differentiation ability and mineralization level of MC3T3-E1 cells were promoted,which was the most obvious in Ber+CA group.Moreover,the mRNA expressions of Wnt3a,β-catenin,ALP,Runx2,OPN,and OCN significantly increased in the Ber+CA group(P<0.01).In vivo experiments showed that compared with those in the model group,serum contents of BALP and BGP in the Ber+CA group significantly reduced,the protein expressions of Wnt3a andβ-catenin significantly increased,and the microstructure of femoral tissue was significantly improved in the Ber+CA group(P<0.05).Moreover,Ber+CA had no obvious damage to the important organ tissue sections of mice,indicating good biosafety.Conclusion Ber combined with CA promotes osteogenic differentiation of MC3T3-E1 cells and improves partial osteoporosis phenotypic characteristics in ovariectomized mice.The mechanism may be related to the activation of Wnt3a/β-catenin signaling pathway.
作者 张晓 刘俊瑾 邵云云 常壮鹏 侯锐钢 ZHANG Xiao;LIU Junjin;SHAO Yunyun;CHANG Zhuangpeng;HOU Ruigang(The Second Clinical Medical College,Shanxi Medical University,Taiyuan 030001,China;Department of Pharmacy,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2023年第7期953-959,共7页 Chinese Journal of Osteoporosis
基金 国家自然科学基金青年基金(82102207) 山西省应用基础研究计划青年项目(20210302124036)。
关键词 小檗碱 绿原酸 骨质疏松 Wnt3a/β-catenin信号通路 berberine chlorogenic acid OVX-induced osteoporosis Wnt3a/β-catenin signaling pathway
  • 相关文献

参考文献11

二级参考文献169

  • 1于雪冰,马建强,汪栋,孙凌.六味地黄丸治疗绝经后骨质疏松症肾阴虚证对骨钙素、骨密度及JAK/STAT信号通路的影响[J].中药材,2020(3):734-737. 被引量:29
  • 2江涛,陈新宇.阿仑膦酸钠治疗绝经后骨质疏松症的疗效[J].慢性病学杂志,2020(12):1909-1911. 被引量:3
  • 3郭启煜.α-葡萄糖苷酶抑制剂:降低餐后高血糖[J].糖尿病新世界,2005(6):42-43. 被引量:4
  • 4Adami S,Bertoldo F,Brandi ML,Cepollaro C Filipponi P Fiore E Frediani B Giannini S Gonnelli S Isaia GC Luisetto G Mannarino E Marcocci C Masi L Mereu C Migliaccio S Minisola S Nuti R Rini G Rossini M Varenna M Ventura L Bianchi G. Guidelines for the diagnosis,prevention and treatment of osteoporosis[J].{H}Reumatismo,2009.260-284.
  • 5Whitaker M,Guo J,Kehoe T,Benson G. Bisphosphonates for osteoporosis-Where do we go from here[J].N Engl J Med,2012.2048-2051.
  • 6Black DM,Bauer DC,Schwartz AV,Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long[J].{H}New England Journal of Medicine,2012.2051-2053.
  • 7Liberman UA,Weiss SR,Br?ll J,Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J,Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group[J].{H}New England Journal of Medicine,1995.1437-1443.
  • 8Bone HG,Hosking D,Devogelaer JP,Tucci JR Emkey RD Tonino RP Rodriguez-Portales JA Downs RW Gupta J Santora AC Liberman UA Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteo-porosis in postmenopausal women[J].{H}New England Journal of Medicine,2004.1189-1199.
  • 9Black DM,Cummings SR,Karpf DB,Cauley JA, Thompson DE, Nevitt MC,Bauer DC,Genant HK,Haskell WL,Marcus R,Ott SM,Torner JC,Quandt SA,Reiss TF,Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group[J].{H}LANCET,1996.1535-1541.
  • 10Black DM,Thompson DE,Bauer DC,Ensrud K, Musliner T, Hochberg MC, Nevitt MC,Suryawanshi S,Cummings SR. Frac-ture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial. FIT Research Group[J].{H}Journal of Clinical Endocrinology and Metabolism,2000.4118-4124.

共引文献148

同被引文献18

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部